Abstract
In this issue of Blood , Heider et al describe the preclinical development of a novel Fc-engineered monoclonal antibody targeting the B-cell antigen CD37, an antigen that may have very different properties then CD20.[1][1] In 1997, the first monoclonal antibody for treatment of cancer, rituximab,
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
